This announcement is a separate document:
領航醫藥生物科技：與建議出售精優藥業控股有限公司（股份代號： 858）約19.14% 已發行股本及 精優藥業控股有限公司所發行 合共577,170,000 港元之可換股債券 有關之非常重大出售事項及關連交易之完成
INNOVATIVE PHAR: COMPLETION OF VERY SUBSTANTIAL DISPOSAL AND CONNECTED TRANSACTION IN RELATION TO PROPOSED DISPOSAL OF APPROXIMATELY 19.14% OF THE ISSUED SHARE CAPITAL OF AND AN AGGREGATE OF HK$577,170,000 CONVERTIBLE BONDS ISSUED BY EXTRAWELL PHARMACEUTI
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.